Loading clinical trials...
Loading clinical trials...
Acute Control of Chronic Hypertension in Preeclampsia
The purpose of this study is to understand if administration of a personalized dose of the anti-hypertensive medication, labetalol, based on patient's history of preexisting hypertension, will be more effective at controlling severe hypertension during pregnancy, compared to the current standard dosing.
The investigators seek to asses the effect of preexisting hypertension on the patient's response to treatment for severe hypertension in preeclampsia with severe features. The investigators hypothesize that successive administration of 40-60-80 mg of labetolol will reduce time to blood pressure control versus the standard dosing, 20-40-80 mg labetolol, recommended by the American College of Obstetricians and Gynecologists in 2015.
Age
18 - No limit years
Sex
FEMALE
Healthy Volunteers
No
Albany Medical Center Obstetrics and Gynecology
Albany, New York, United States
Start Date
February 18, 2019
Primary Completion Date
July 20, 2020
Completion Date
July 20, 2020
Last Updated
July 22, 2020
10
ACTUAL participants
Experimental dosing of labetalol
DRUG
Standard dosing of labetalol
OTHER
Lead Sponsor
Albany Medical College
NCT05096728
NCT04998942
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT03872336